

POSTER PRESENTATION

Open Access

The effects of ulinastatin in multiple organ failure: a retrospective observational study in a single center ICU

M Uchida^{1*}, T Abe², K Ono¹

From ESICM LIVES 2015

Berlin, Germany. 3-7 October 2015

Introduction

Ulinastatin, an urinary protease inhibitor, might reduce mortality of patients with systemic inflammatory response syndrome such as ARDS [1] and sepsis [2].

Objectives

Our aim was to evaluate the effectiveness of ulinastatin on 28-day mortality among patients with multiple organ failure.

Methods

We conducted a retrospective observational study of patients who were diagnosed multiple organ failure within 24 hours from admission in a general ICU of a tertiary care hospital in Japan. The study duration was from January 2009 to December 2012. The primary outcome was 28-day all cause mortality. The intervention was received ulinastatin for three days and more. Patients were also stratified by category of diseases as subgroup analysis.

Results

A total of 212 patients with multiple organ failure met inclusion criteria during this study period. At baseline, mean age was 66.2 ± 14.7 years old, male was 146/212 (69%), mean APACHE II score was 24.7 ± 7.9 , 206/212 (97 %) patients received mechanical ventilation, and 205/212 (96 %) patients were on vasopressor. Overall, 79/212 (37%) patients received ulinastatin. 28-day all cause mortality was 43/212 (20%). There were no significant differences between ulinastatin group and control group in age, gender, APACHE II score. Ulinastatin group had higher prevalence of sepsis

(35/79 (44.3%) vs. 29/133 (21.8%), $P = 0.001$). They were more likely to receive corticosteroid, vasopressor, renal replacement therapy, and veno-arterial extra-corporeal membranous oxygenation (VA-ECMO). The mortality was not significantly different between the ulinastatin group and control group (20/79 (25.3%) vs. 23/133 (17.3%), $P = 0.163$). In logistic regression after adjusting for APACHE II score, there was not significant difference in the mortality (OR = 1.59; 95% CI, 0.79 - 3.21). The result was similar after adjusting for APACHE II score, sepsis, respiratory disorder, therapeutic interventions including corticosteroid, vasopressor, renal replacement therapy, and VA-ECMO. (OR = 1.29; 95% CI, 0.56 - 2.99). In sepsis patients, ulinastatin did not reduce the mortality, either. (OR = 1.92; 95% CI, 0.52 - 7.13).

Conclusions

Ulinastatin was not associated with survival in patients with multiple organ failure.

Authors' details

¹Dokkyo Medical University, Department of Emergency and Critical Care Medicine, Shimotsuga-gun Mibu-machi, Japan. ²Tsukuba Medical Center Hospital, Department of Emergency and Critical Care Medicine, Tukuba-shi, Japan.

Published: 1 October 2015

References

1. Leng Y-X, et al: Ulinastatin for acute lung injury and acute respiratory distress syndrome: A systematic review and meta-analysis. *World J Crit Care Med* 2014, **3**:34-41.
2. Karnad DR, et al: Intravenous administration of ulinastatin (human urinary trypsin inhibitor) in severe sepsis: a multicenter randomized controlled study. *Intensive Care Med* 2014, **40**:830-8.

doi:10.1186/2197-425X-3-S1-A878

Cite this article as: Uchida et al: The effects of ulinastatin in multiple organ failure: a retrospective observational study in a single center ICU. *Intensive Care Medicine Experimental* 2015 **3**(Suppl 1):A878.

¹Dokkyo Medical University, Department of Emergency and Critical Care Medicine, Shimotsuga-gun Mibu-machi, Japan
Full list of author information is available at the end of the article